Chad Robins Sells 83,332 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 83,332 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $14.41, for a total value of $1,200,814.12. Following the completion of the sale, the chief executive officer directly owned 2,217,781 shares in the company, valued at approximately $31,958,224.21. This represents a 3.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT traded up $1.13 during trading hours on Wednesday, reaching $14.84. 2,188,850 shares of the company were exchanged, compared to its average volume of 2,046,190. The company has a market capitalization of $2.29 billion, a P/E ratio of -37.10 and a beta of 2.29. Adaptive Biotechnologies Corporation has a 1-year low of $6.77 and a 1-year high of $20.76. The business has a 50 day moving average of $15.17 and a 200 day moving average of $15.98.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.23) earnings per share. As a group, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $28,000. Sound Income Strategies LLC purchased a new position in Adaptive Biotechnologies in the third quarter worth $30,000. EverSource Wealth Advisors LLC grew its position in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. grew its position in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Adaptive Biotechnologies in the fourth quarter worth $51,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on ADPT. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. BTIG Research raised their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. increased their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.